Founders

Nuno Costa-Borges, PhD

Scientific director

参与完成西班牙第一例动物克隆 • 参与完成欧洲首例应用PiezoDrill的马匹胚胎活检 • 担任Eppendorf胚胎显微操作的独立科学顾问 • 在临床胚胎学和IVF实验室质控方面拥有丰富经验 • 受邀担任葡萄牙里斯本Champalimaud Foundation癌症研究中心讲师 • 同行审阅杂志发表多篇文章和摘要，包括：Human Reproduction; Reproduction; Cellular Reprogramming; Cloning and Stem Cells; Theriogenology; Reproduction Fertility and Development等. • 曾在ESHRE, AETE, ASEBIR发表大量口述交流和科学壁报 • 获西班牙、波兰、德国的科学组织颁授奖项 • 操流利葡萄牙语、英语、西班牙语和加泰罗尼亚语。

Gloria Calderón, PhD

Former President

西班牙IVF之母，作为主要人员参与完成西班牙第一例试管婴儿。 • 在IVF科学领域逾30年的经验，擅长的专业领域包括临床胚胎学、实验室质控、和实验室设计等方面。 • 自2000年担任西班牙IVI集团（逾2.5万周期/年）首席科学顾问及实验室代表。 • 担任西班牙6所大学的硕士生导师。 • 自1991年开始应邀到全球IVF中心进行指导，包括西班牙、英国、法国、比利时、希腊、巴西、阿根廷、墨西哥、土耳其、智利、秘鲁等。 • 曾受邀到欧洲、美洲、亚洲、中东等30多个国家的生殖会议和研讨会（包括ESHRE等）担任讲师 • 在Human Reproduction, Fertility and Sterility, EHSRE, ASRM等国际会议及知名生殖杂志发表超过200多篇论文和摘要 • Human Reproductive Medicine 复核委员会成员

General management

实验室工作人员

Enric Mestres, PhD

Laboratory director

Embryology laboratory

Mònica Acacio, MSc

Head of Vet Center & Research coordinator

Embryology laboratory

Alba Casals, Tech

Laboratory coordinator

Quality control laboratory

Andrea Villamar, Tech

Co-Head of QC Center

Quality control laboratory

Queralt Matia, MSc

Head of Products Center

Embryology laboratory

Carolina Castelló, BSc

Head of the Training Center

Embryology laboratory

Albert Martínez, MSc

Co-head of QC Center

Quality control laboratory

Aina Franco, MSc

 

Quality control laboratory

Lydia Romera, MSc

 

Quality control laboratory

Pau Soler, Tech

胚胎

Quality control laboratory

Sonia Gago, MSc

PhD Student

Embryology laboratory

Carlota Gutiérrez, MSc

 

Embryology Laboratory

行政

外部科学顾问

Dagan Wells, PhD

Scientific Advisor

Dagan Wells has been actively involved in preimplantation genetic diagnosis (PGD) and the study of human gametes and embryos for over two decades, conducting his first PGD cases in 1992. He spent several years developing novel PGD tests at University College London, accomplishing the first comprehensive chromosome analysis of cells from human embryos in 1998, using a combination of whole genome amplification and comparative genomic hybridisation (CGH). In 1999 Dagan moved to the United States and joined Reprogenetics, one of the world’s largest providers of PGD services. In 2003 he initiated Reprogenetics’ highly successful single gene PGD program, testing embryos for numerous serious inherited conditions. Dagan later joined the faculty of Yale University Medical School, where he spent four years running a research laboratory, before returning to the UK in late 2007. His research group is now located in the Nuffield Department of Obstetrics and Gynaecology at the University of Oxford. Dagan’s work has led to the publication of more than 120 peer-review publications and book chapters and has been recognized with the award of numerous prizes and grants. He is a Fellow of the Royal College of Pathologists and currently serves on the Editorial Boards of several international journals. Dagan also directs Reprogenetics-UK, an independent laboratory offering state-of-the-art PGD services to IVF clinics throughout the UK and internationally.

Klaus Rink, PhD

Scientific Advisor

German physicist, specialized in experimental physics, fluent in English and French. He is renowned for research and development of laser products for medical applications in the fields of in vitro fertilization, tissue welding and the treatment of kidney stones. In 2000 he co-founded OCTAX Microscience GmbH in Germany. OCTAX develops and manufactures IVF medical equipment, ranging from therapeutic to diagnostics appliances. OCTAX is reputed worldwide for producing the most reliable and accurate laser equipment, researched and developed by Dr. Rink since 1992. Scientific achievements: /1st birth after laser assisted hatching (1.48 μm) /1st birth after laser assisted blastomere biopsy and PGD /1st birth after laser assisted polar body biopsy /1st birth after laser assisted immobilization of spermatozoa /1st pregnancy after laser assisted zona drilling for ICSI /1st pregnancy after laser assisted removal of necrotic blastomeres from cryopreserved embryos

Gabriel Clérico

Veterinary

Gabriel José Clérico is a distinguished Argentinian biotechnologist specializing in equine reproductive technologies. He has played a pivotal role in advancing assisted reproduction in horses, particularly in the areas of oocyte vitrification and intracytoplasmic sperm injection (ICSI). In a landmark study published in Theriogenology in 2021, Clérico and his team reported the successful birth of live foals from vitrified/warmed immature equine oocytes matured with or without melatonin supplementation. This achievement marked a significant milestone in equine reproductive science, demonstrating the viability of vitrified oocytes in producing healthy offspring. Beyond his groundbreaking work in oocyte vitrification, Clérico has contributed to the broader field of equine assisted reproduction through studies on oocyte maturation dynamics and the timing of polar body extrusion, further informing best practices in ICSI procedures. Gabriel Clérico's contributions have not only advanced scientific understanding but have also had practical implications for equine breeding programs, offering new avenues for preserving and propagating valuable genetic lines.  

Xavier Santamaria, M.D., PhD

Scientific Medical Advisor

Board Ob/Gyn specialist in Reproductive Medicine. He obtained a post-graduate fellowship in Reproductive Endocrinology and Infertility at Yale University (USA) and completed his Ph.D. at the Universitat Autònoma Barcelona (Spain). Dr. Santamaria war the Director of the International Department at the IVI between 2012 and 2016. In 2016, he joined Dr. Simon's Research group as a Senior Principal Investigator, where he has developed his research related to Asherman's Syndrome. His mail clinical and scientific interest is in understanding the regenerative capacity of the human endometrium and developing strategies to regenerate the endometrium to improve embryo implantation. His group was the first to complete a trial using human bone marrow stem cells to treat Asherman's syndrome and endometrial atrophy (PMDI:27005892) demonstrating this approach's feasibility in treating endometrial pathologies. As a result, CD133+ cells have been designed as the first Orphan Drug (ODD) by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) in the field of gynecological research. Dr. Santamaria has also participated as an inventor in 7 different patent applications, and is a co-founder and scientific director of 4 different start-up companies. He has published 27 papers in peer-reviewed journals (H-index of 15) and 12 book chapters. He has been an invited speaker at more than 70 international conferences and was awarded the prize for Best Oral Presentation for Young Investigators at the Society of Ginecological Investigation Meeting in 2009. He has directed one doctoral thesis.

Business Advisor